Evidence gap
A values / turf tradeoff — more data alone will not resolve it.
Resolves via: Shared decision-making + role clarity
Get the thresholds wrong and millions of low-risk adults start lifelong statins they may never have needed — or get them right and you finally catch the patients who slip through current risk scores.
Active since Apr 2024
The debate
31 clinicians quoted on the record
Lower thresholds plus once-in-a-lifetime Lp(a) testing catch high-risk people that older risk equations miss, and starting statins earlier in the right patients prevents events decades down the line.
“There is indeed overwhelming evidence supporting our practice-changing Guideline.”
“LDL-C and non-HDL-C treatment goals are back to guide lipid-lowering therapy.”
+ 4 more on this side
Many of these new Class I recommendations rest on modeling and observational data rather than randomized outcome trials, so lowering the bar risks medicating large numbers of people who would never have had an event.
“Too many Class I recommendations lacking supporting data from randomized trials.”
Where the experts land
6–1 on record · 24 unplaced
Appropriately intensifies prevention · 6
On the record, unplaced · 24
Will over-treat the well · 1
“It is great to see the 2026 ACC/AHA/Multisociety Dyslipidemia Guideline restore LDL-C treatment goals.”
Where the field stands
Common ground
Everyone agrees Lp(a) is a real, inherited, measurable risk factor that most patients have never had checked.
The crux
Whether a universal screening mandate is justified now, or should wait until a drug proves that lowering Lp(a) prevents events.
Still unknown
A positive outcome trial for an Lp(a)-lowering agent would settle it almost overnight; a neutral one would gut the case for mass testing.
On the record
Their own words — position stated as published
universal screening
“Everyone needs Lp(a) testing — once. It should be considered as a risk-enhancing factor.”
Steven Nissen · Cardiologist · 3 statements · NBC News ↗
support universal screening
“For the first time in a US guideline, universal Lp(a) measurement is recommended at least once in all adults, carrying a Class I designation.”
Ann Marie Navar · Preventive cardiologist · 2 statements · HCP Live ↗
ACC/AHA approach
“The 2026 ACC/AHA guideline restores treatment goals for LDL-C based on risk.”
Blumenthal RS · Guideline writing committee chair · 2 statements · NLA ↗
earlier detection, not necessarily universal early statins
“This is why we are emphasizing checking cholesterol at a young age — not because we want to start everybody on statins early, but because having high cholesterol for a long time makes it more likely that someone will have a heart attack or stroke.”
Leslie Cho · Guideline co-author; Cleveland Clinic preventive cardiology · 2 statements · Cleveland Clinic ↗
Where do you land?
No votes yet — the measured split appears at 10.
Where the evidence stands
2026 US lipid guidance advises CAC when statin decisions are uncertain and treats any CAC as support to start a statin. PREVENT already lowered risk estimates, so CAC is being used both to 'de-risk' and to 're-risk.' There is still no large RCT showing CAC-guided treatment cuts events versus treating by risk score alone. Radiation, incidental findings, and equity of access are live objections.
What's settled
4What's still open
4How this gets settled
A values / turf tradeoff — more data alone will not resolve it.
Who could settle it
Know an expert who could settle this? Suggest one →
Who this affects
Who could fund or run it
Institutions that could fund, run, or adopt
Sources & verification
+ 111 more, each dated and verification-tagged
Who we found publicly on the record — a snapshot, not a poll of the field. Larger dots are deciders; dashed dots are scan-reported, not yet verified.